Eisai says UK biz to be impacted by concessions to NHS; to continue breast cancer treatment for now

23 July 2015

Japanese drug major Eisai (TYO: 4523) said its activity in the UK may be impacted by the substantial concessions to the National Health Service in a bid to continue the inclusion of its breast cancer treatment Halaven (eribulin) in the Cancer Drugs Fund (CDF).

The pharmaceutical company said the negotiations with the NHS may also affect the future treatment options available to patients in the UK.

Chief executive of the company’s EMEA region, Gary Hendler, said: “Eisai has had to negotiate a short-sighted, simplistic and short-term agreement to ensure the needs of patients were met and Halaven retains its rightful place on the CDF.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK